ArticleFrontiers in nutrition2022
Serum creatinine to cystatin C ratio and clinical outcomes in adults with non-dialysis chronic kidney disease.
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Sarcopenia defined by serum creatinine and cystatin C predicts poor survival outcomes in patients with cancers.BMC geriatrics · 2025Pooled it
- Creatinine-to-cystatin C ratio as muscle assessment tool and predictive value for mortality and sarcopenia in patients with chronic kidney disease: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- Predictive role of baseline serum creatinine-to-cystatin C ratio for renal dysfunction incidence in patients with acute ischemic stroke.BMC nephrology · 2026Trial
- Pilot Study of Diagnostic Performance of Serum Creatinine/Cystatin C Ratio for Pseudo-AKI.Kidney international reports · 2026Article
- Associations of Creatinine Muscle Index with markers of sarcopenia and mortality in chronic kidney disease: A prospective cohort study.PLoS medicine · 2026Article
- Association Between Sarcopenia Index and Central Obesity: Age- and Gender-Specific Patterns and Clinical Implications.International journal of general medicine · 2026Article
- The creatinine-to-cystatin C ratio as a prognostic risk-stratification biomarker in chronic kidney disease.Frontiers in nutrition · 2026Article
- Predictive value of creatinine-cystatin C ratio for mortality and technique failure in anuric peritoneal dialysis patients.Renal failure · 2025Article
- Article
- Bidirectional relationship between serum creatinine to cystatin C ratio and chronic kidney disease: a mediation analysis of depression in a national aging cohort.Frontiers in psychiatry · 2025Article
- Cardiometabolic multimorbidity in relation to the metabolic score for insulin resistance and creatinine-to-cystatin C ratio in a middle-aged and aged population.Frontiers in endocrinology · 2025Article
- Large Discordance between Creatinine-Based and Cystatin C-Based eGFRs is Associated with Falls, Hospitalizations, and Death in Older Adults.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.Annals of surgical oncology · 2024Article
- Creatinine-cystatin C ratio and death with a functioning graft in kidney transplant recipients.Scientific reports · 2024Article
- Sarcopenia and myosteatosis diagnostic tool for gastrointestinal cancer: creatinine to cystatin C ratio as evaluation marker.Journal of translational medicine · 2023Article
- The Association between Serum Creatinine/Cystatin C Ratio and Cardiovascular Morbidity and Mortality: Insights from NHANES.Reviews in cardiovascular medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies have suggested that the serum creatinine/cystatin C (Cr/CysC) ratio is a surrogate marker for muscle wasting is associated with adverse outcomes in several disease conditions. To clarify the utility of the Cr/CysC ratio as a prognostic marker in chronic kidney disease (CKD) we evaluated the association between the Cr/CysC ratio clinical outcomes in patients with non-dialysis CKD. Methods: This prospective observational cohort study included 1,966 participants of the KoreaN cohort study Outcomes in patients With CKD (KNOW-CKD). We evaluated associated factors with the serum Cr/CysC ratio and association between the serum Cr/CysC ratio and composite outcomes of all-cause death and cardiovascular events (CVEs). Results: The mean age was 54 ± 12 (SD) years and 61% were men. The mean serum Cr/CysC ratio was 10.97 ± 1.94 in men and 9.10 ± 1.77 in women. The Cr/CysC ratio correlated positively with urinary creatinine excretion, a marker of muscle mass. In the fully adjusted Cox proportional hazard model, the Cr/CysC ratio was associated with the occurrence of adverse outcomes through a median follow-up of 5.9 years [hazard ratio (HR) = 0.92, 95% confidence interval (CI) = 0.85-0.99 for the composite outcomes, HR = 0.87, 95% CI, 0.78 - 0.97 for all-cause death, and HR = 0.93; 95% CI, 0.84-1.04 for CVEs]. In subgroup analyses, there were interactions of the Cr/CysC ratio with age and sex for risk of the clinical outcomes, but not eGFR group. Conclusion: A higher Cr/CysC ratio is associated with a lower risk of the composite outcomes, especially all-cause mortality, even after adjusting for eGFR. These suggest that the Cr/CysC ratio is a useful prognostic marker in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.